| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 148, Issue 4 1176-1181, Copyright © 1992 by American Association of Immunologists
ARTICLES |
MJ Carrier, SN Chatfield, G Dougan, UT Nowicka, D O'Callaghan, JE Beesley, S Milano, E Cillari and FY Liew
Wellcome Research Laboratories, Beckenham, Kent, England.
The feasibility of using Salmonella typhimurium aroA mutant (SL3261) to deliver protein therapeutic agents was investigated in a murine model system. We have constructed an Escherichia coli expression plasmid designed to express the human protein IL-1 beta. This plasmid expresses IL-1 beta to high levels (greater than 30% total cell protein) in E. coli. In Salmonella the IL-1 beta is expressed constitutively to about 10% total cell protein, as verified by Western blotting analysis using polyclonal rabbit anti-IL-1 beta antibody. The protein is produced in a soluble and biologically active form. BALB/c mice administered orally or i.v. with S. typhimurium aroA mutants carrying the plasmid produced highly significant antibody responses against human IL-1 beta as determined by a solid-phase RIA. Furthermore, mice injected with the construct were significantly protected against lethal gamma-irradiation (850 rad). This study therefore demonstrates that the vaccine strain of Salmonella mutants can also be used effectively to deliver therapeutic proteins in vivo.
This article has been cited by other articles:
|
|
 |
|
  M. Loeffler, G. Le'Negrate, M. Krajewska, and J. C. Reed Inhibition of Tumor Growth Using Salmonella Expressing Fas Ligand J Natl Cancer Inst, August 6, 2008; 100(15): 1113 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Loeffler, G. Le'Negrate, M. Krajewska, and J. C. Reed Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth PNAS, July 31, 2007; 104(31): 12879 - 12883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Toso, V. J. Gill, P. Hwu, F. M. Marincola, N. P. Restifo, D. J. Schwartzentruber, R. M. Sherry, S. L. Topalian, J. C. Yang, F. Stock, et al. Phase I Study of the Intravenous Administration of Attenuated Salmonella typhimurium to Patients With Metastatic Melanoma J. Clin. Oncol., January 1, 2002; 20(1): 142 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. al-Ramadi, M. H. Al-Dhaheri, N. Mustafa, M. AbouHaidar, D. Xu, F. Y. Liew, M. L. Lukic, and M. J. Fernandez-Cabezudo Influence of Vector-Encoded Cytokines on Anti-Salmonella Immunity: Divergent Effects of Interleukin-2 and Tumor Necrosis Factor Alpha Infect. Immun., June 1, 2001; 69(6): 3980 - 3988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Wyant, M. K. Tanner, and M. B. Sztein Salmonella typhi Flagella Are Potent Inducers of Proinflammatory Cytokine Secretion by Human Monocytes Infect. Immun., July 1, 1999; 67(7): 3619 - 3624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M L Huggins, F-P Huang, D Xu, G Lindop, and D I Stott Modulation of autoimmune disease in the MRL-lpr/lpr mouse by IL-2 and TGF-{beta}1 gene therapy using attenuated Salmonella typhimurium as gene carrier Lupus, January 1, 1999; 8(1): 29 - 38. [Abstract] [PDF]
|
|
|
|
|
|
L. Steidler, K. Robinson, L. Chamberlain, K. M. Schofield, E. Remaut, R. W. F. Le Page, and J. M. Wells Mucosal Delivery of Murine Interleukin-2 (IL-2) and IL-6 by Recombinant Strains of Lactococcus lactis Coexpressing Antigen and Cytokine Infect. Immun., July 1, 1998; 66(7): 3183 - 3189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Xu, S. J. McSorley, L. Tetley, S. Chatfield, G. Dougan, W. L. Chan, A. Satoskar, J. R. David, and F. Y. Liew Protective Effect on Leishmania major Infection of Migration Inhibitory Factor, TNF-{alpha}, and IFN-{gamma} Administered Orally via Attenuated Salmonella typhimurium J. Immunol., February 1, 1998; 160(3): 1285 - 1289. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
